Nektar Therapeutics (NASDAQ:NKTR) posted its quarterly earnings data on Thursday. The biopharmaceutical company reported ($0.57) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.70) by $0.13, RTT News reports. Nektar Therapeutics had a net margin of 59.71% and a return on equity of 79.66%. During the same quarter in the prior year, the business posted ($0.21) earnings per share.
NKTR stock traded down $3.78 during mid-day trading on Friday, hitting $36.76. 91,766 shares of the company were exchanged, compared to its average volume of 1,836,665. The company has a quick ratio of 13.80, a current ratio of 13.93 and a debt-to-equity ratio of 0.14. The company has a market capitalization of $6.93 billion, a PE ratio of -66.76 and a beta of 3.03. Nektar Therapeutics has a 1-year low of $29.22 and a 1-year high of $111.36.
A number of equities analysts have recently commented on the stock. Mizuho restated a “buy” rating and set a $81.00 price objective on shares of Nektar Therapeutics in a research note on Wednesday, January 23rd. ValuEngine upgraded shares of Nektar Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, January 15th. HC Wainwright reiterated a “hold” rating and issued a $47.00 target price on shares of Nektar Therapeutics in a research note on Tuesday, February 19th. Zacks Investment Research downgraded shares of Nektar Therapeutics from a “buy” rating to a “hold” rating in a research note on Monday, January 14th. Finally, BMO Capital Markets started coverage on shares of Nektar Therapeutics in a research note on Friday, February 22nd. They issued an “outperform” rating and a $75.00 target price for the company. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and ten have assigned a buy rating to the company. The stock presently has an average rating of “Buy” and an average price target of $79.45.
In other Nektar Therapeutics news, COO John Nicholson sold 63,000 shares of the firm’s stock in a transaction that occurred on Monday, January 28th. The shares were sold at an average price of $42.82, for a total transaction of $2,697,660.00. Following the completion of the sale, the chief operating officer now directly owns 237,477 shares in the company, valued at $10,168,765.14. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CAO Jillian B. Thomsen sold 1,808 shares of the firm’s stock in a transaction that occurred on Tuesday, February 19th. The stock was sold at an average price of $42.39, for a total transaction of $76,641.12. The disclosure for this sale can be found here. Insiders have sold 241,824 shares of company stock valued at $10,249,993 over the last 90 days. Company insiders own 4.31% of the company’s stock.
About Nektar Therapeutics
Nektar Therapeutics, a research-based biopharmaceutical company, discovers and develops drug candidates for cancer, auto-immune disease, and chronic pain in the United States. The company offers ONZEALD, a topoisomerase I inhibitor that is in Phase III clinical trial for advanced metastatic breast cancer in patients with brain metastases; NKTR-181, an orally-available mu-opioid analgesic molecule, which is in Phase III clinical trial for moderate to severe chronic pain; NKTR-214, a cytokine immunostimulatory therapy that is in Phase I/II to treat cancer; NKTR-358, which is in Phase I to treat autoimmune diseases; and NKTR-262 for solid tumors, as well as NKTR-255 that is under research/preclinical stage for immuno-oncology.
Read More: Calculate Your Return on Investment (ROI)
Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.